Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moxalactam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.80 |
| ▸ | CMA1 | P23946 | 18/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moxalactam SCHEMBL194012 | 1.00 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL49017 | 1.00 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL49016 | 1.00 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL194013 | 1.00 | PTGS1 (1.00) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL951858 | 0.99 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL584454 | 0.99 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL951857 | 0.99 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL10694935 | 0.99 | PTGS1 (0.99) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL9800360 | 0.99 | PTGS1 (0.97) | PTGS1HSD17B10TDP1CMA1 | |
| Moxalactam SCHEMBL3382938 | 0.93 | PTGS1 (0.87) | PTGS1HSD17B10TDP1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096858-A1 | Method of Stabilizing Disordered Cefovecin Sodium Salt | UNIVERSITY OF CONNECTICUT (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096858-A1 | Method of Stabilizing Disordered Cefovecin Sodium Salt | CHAMP1, PEF1, DDOST | PTGS1 4652/4885HSD17B10 935/4885TDP1 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.